SEC Tracker
Get the app

Flora Growth ZSTK

Flora Growth FY 2022: revenue $37.2M, up 314%; diluted EPS −$13.68

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Flora Growth reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$37.2M+314% from $9.0M in FY 202110-K income statement, on EDGAR
  2. Net income−$52.6MAgainst −$21.4M in FY 202110-K income statement, on EDGAR
  3. Diluted EPS−$13.68No year-earlier figure tagged10-K income statement, on EDGAR
  4. Cash and cash equivalents$9.5M−75% from $37.6M in FY 202110-K balance sheet, on EDGAR
  5. Cash from operations−$15.9MAgainst −$20.9M in FY 202110-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Flora Growth files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 6199 and related industry codes: the same peer list as the financial tables.

  1. Marblegate Capital MGTE public float $12M, Jun 30, 2025
  2. Applied Dna Sciences APDN public float $11M, Mar 31, 2025, over 18 months old
  3. HeartSciences HSCS public float $10M, Oct 31, 2025
  4. FG Nexus FGC public float $13M, Jun 30, 2025
  5. Marygold Companies MGLD public float $9M, Dec 31, 2025